kinase inhibitor articles & resources on Made-in-China.com

Sunesis Pharmaceuticals Has Expanded Its Hematology Franchise

Jan 13, 2014

Sunesis Pharmaceuticals has expanded its hematology franchise through separate global licensing agreements for two preclinical kinase inhibitor programs. The first agreement, with Biogen Idec, is for global commercial rights to SNS-062, a ...

Tags: Sunesis Pharmaceuticals, Medicine

BIND Therapeutics Amended Its Development and Commercialization Collaboration Agreement

Dec 16, 2013

BIND Therapeutics, a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins, has amended its development and commercialization collaboration agreement with Amgen to extend the period ...

Tags: BIND Therapeutics, Kinase Inhibitor Nanomedicine

The FDA Has Approved Nexavar for The Treatment of Locally Recurrent or Metastatic

Nov 26, 2013

Germany-based Bayer HealthCare and US-based Onyx Pharmaceuticals have announced that the US Food and Drug Administration (FDA) has approved Nexavar (sorafenib), an oral multi-kinase inhibitor, for the treatment of patients with ...

Tags: Health, Medicine

Ignyta Has Entered Into a License Agreement with Nerviano Medical Sciences

Nov 6, 2013

US-based biotechnology firm Ignyta has entered into a license agreement with Nerviano Medical Sciences (Nerviano), under which Ignyta will get exclusive global development and marketing rights of tyrosine kinase inhibitors RXDX-101 and ...

Tags: Ignyta, Tyrosine Kinase Inhibitors

Loxo Oncology Acquired Rights to This Program From Array Biopharma

Oct 30, 2013

US-based Loxo Oncology has announced that its lead clinical program is a potent and selective inhibitor of the Trk family of receptor tyrosine kinases. Loxo Oncology acquired rights to this program from Array Biopharma, which had pursued ...

Tags: Loxo Oncology, Medicine

Tracon Has Started Dosing in a Phase Ib Clinical of TRC105 for The Treatment of Patients

Sep 25, 2013

US-based biopharmaceutical firm Tracon Pharmaceuticals has started dosing in a Phase Ib clinical of TRC105 for the treatment of patients with metastatic renal cell carcinoma. The trial evaluates the combination of TRC105 and a standard ...

Tags: Tracon, Carcinoma Drug

EMA Has Received an Application From Bayer HealthCare for Marketing Authorization

Sep 10, 2013

The European Medicines Agency (EMA) has received an application from Bayer HealthCare for marketing authorization of its oral multi-kinase inhibitor, regorafenib, for the treatment of patients with gastrointestinal stromal tumors (GlST). ...

Tags: Bayer, Medicine

Bayer and Onyx Have Announced FDA Priority Review Designation

Aug 29, 2013

Bayer HealthCare and Onyx Pharmaceuticals have announced FDA priority review designation for Nexavar (sorafenib) supplemental new drug application for the treatment of radioactive iodine-refractory differentiated thyroid cancer. Nexavar ...

Tags: New Drug Application, FDA

FDA Has Cleared Gilotrif as a New Medication for Patients with Late Stage NSCLC

Jul 16, 2013

The US Food and Drug Administration (FDA) has cleared Boehringer Ingelheim's tyrosine kinase inhibitor Gilotrif (afatinib) as a new medication for patients with late stage (metastatic) non-small cell lung cancer (NSCLC). The approval also ...

Tags: FDA, Lung Cancer Therapy, Medicine

Janssen Research & Development Is Seeking FDA Approval for Use Ibrutinib in The Treatment

Jul 12, 2013

Janssen Research & Development is seeking FDA approval for use of ibrutinib in the treatment of previously treated patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), and mantle cell lymphoma (MCL). The ...

Tags: FDA Approval, Janssen

Ariad Pharmaceuticals Submitted NDA for Its Investigational BCR-ABL Inhibitor

Dec 7, 2012

US based Ariad Pharmaceuticals has submitted New Drug Application (NDA) for its investigational BCR-ABL inhibitor, ponatinib for the approval of US Food and Drug Administration (FDA). Ponatinib is indicated for patients with resistant or ...

Tags: BCR-ABL inhibitor, CML, Ph+ALL

Proacta Announced FDA Approval of Investigational New Drug Application for PR610

Dec 6, 2012

Proacta, a San Diego based biotechnology company, has announced FDA approval of investigational new drug (IND) application for PR610, a hypoxia-activated irreversible multi-kinase inhibitor, for the treatment of cancer. With the IND ...

Tags: investigational new drug, IND

FDA Approved Pfizer's Bosulf to Treat Adult Patients with PH+ CML

Dec 5, 2012

US Food and Drug Administration (FDA) has approved Pfizer's Bosulf (bosutinib) to treat adult patients with chronic, accelerated or blast phase Philadelphia chromosome-positive (Ph+) (CML) with resistance to prior therapy. Bosulif is a ...

Tags: bosulf, bosutinib, kinase inhibitor, Philadelphia chromosome-positive

Bayer Healthcare Filed NDA with The FDA Seeking Approval for Inhibitor Regorafenib

Dec 5, 2012

Bayer HealthCare has filed a new drug application (NDA) with the FDA seeking approval for the oral multi-kinase inhibitor regorafenib to treat patients with metastatic colorectal cancer (mCRC). The company has even filed an application ...

Tags: oral multi-kinase inhibitor regorafenib, metastatic colorectal cancer

Bayer HealthCare Submitted Submitted NDA

Dec 4, 2012

Bayer HealthCare has submitted has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its regorafenib drug. The oral multi-kinase inhibitor regorafenib is used for the treatment of metastatic and ...

Tags: NDA, FDA, inhibitor, metastatic, GIST

kinase inhibitor

Related Products